Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy adults between the ages of 18 and 55 years old.~2. Male or female~Exclusion Criteria:~1. Presence of clinically significant cardiovascular, endocrine, hematopoietic, hepatic, neurologic, psychiatric, or renal disease or pregnancy.~2. Presence or history of drug or alcohol abuse.~3. The use of concomitant medications, which are known to affect ESL or Carbamazepine or the use of any concomitant medications that may alter cognitive function (see Section VII.E for a partial list).~4. Use of oral contraceptive hormones or other medications that could be affected by ESL or Carbamazepine.~5. Prior adverse reaction to or prior hypersensitivity to either study medication or to related compounds.~6. Prior participation in studies involving anticonvulsant medications.~7. Subjects who have received any investigational drug within the previous thirty days.~8. Subjects with IQ \< 70 as determined by the Peabody Picture Vocabulary Test.~9. Presence of HLA B\*1502 in subjects of Asian descent; this will be obtained at screening in subjects of Asian descent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Eslicarbazepine (Type: EXPERIMENTAL): Randomized to eslicarbazepine 800mg po bid in crossover design.
- Carbamazepine (Type: EXPERIMENTAL): Randomized to carbamazepine 400mg po bid in crossover design.

Based on this trial design, predict the completion outcome and termination type (if applicable).